GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HBM Holdings Ltd (FRA:6XY) » Definitions » Valuation Rank

HBM Holdings (FRA:6XY) Valuation Rank


View and export this data going back to 2021. Start your Free Trial

What is HBM Holdings Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

HBM Holdings Valuation Rank Related Terms

Thank you for viewing the detailed overview of HBM Holdings's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

HBM Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HBM Holdings Ltd (FRA:6XY) » Definitions » Valuation Rank
Comparable Companies
HKSE:02315 HKSE:02105 HKSE:02157 HKSE:01672 HKSE:09966 HKSE:02256 HKSE:00775 HKSE:02480 HKSE:06660 HKSE:02171 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
HBMHF:USA 02142:Hong Kong
Address
218 Xinghu Street, Suite 202, Building A3, Suzhou Industrial Park, Suzhou, CHN, 215123
Website
https://www.harbourbiomed.com
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the United States.